A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
Stopped Available clinical data has shown limited anti-tumor activity and reaching target study drug dose levels may not be feasible.
Conditions
Interventions
- DRUG: Avelumab
- DRUG: Binimetinib
- DRUG: Talazoparib
Sponsor
Pfizer